您所在的位置:首頁 > 腎內(nèi)科診療指南 > 2013AUA腎癌隨訪指南
Purpose: The Panel sought to create evidence-based guidelines for the follow-upand surveillance of clinically localized renal cancers treated with surgery or renalablative procedures, biopsy-proven untreated clinically localized renal cancersfollowed on surveillance, and radiographically suspicious but biopsy-unprovenrenal neoplasms either treated with renal ablative procedures or followed onactive surveillance. These guidelines are not meant to address hereditary orpediatric kidney cancers, although they must take into account that a proportionof adult patients may harbor a yet unrecognized hereditary form of renal cancer.
Methods: A systematic review was conducted to identify published articlesrelevant to key questions specified by the Panel related to kidney neoplasms andtheir follow-up (imaging, renal function, markers, biopsy, prognosis). This searchcovered English-language articles published between January 1999 and 2011. Anupdated query was later conducted to include studies published through August2012. These publications were used to inform the statements presented in theguideline as Standards, Recommendations or Options. When sufficient evidenceexisted, the body of evidence for a particular treatment was assigned a strengthrating of A (high), B (moderate) or C (low). In the absence of sufficient evidence,additional information is provided as Clinical Principles and Expert Opinion.
GUIDELINE STATEMENTS
1.Patients undergoing follow-up for treated or observed renal masses shouldundergo a history and physical examination directed at detecting signs andsymptoms of metastatic spread or local recurrence. (Clinical Principle)
2.Patients undergoing follow-up for treated or observed renal masses shouldundergo basic laboratory testing to include blood urea nitrogen (BUN)/creatinine, urine analysis (UA) and estimated glomerular filtration rate (eGFR).Other laboratory evaluations, including complete blood count (**), lactatedehydrogenase (LDH), liver function tests (LFTs), alkaline phosphatase (ALP)and calcium level, may be used at the discretion of the clinician. (ExpertOpinion)
完整版下載 2013AUA腎癌隨訪指南
腎臟亦是參與機體代謝的器官之一,尤其是在水、電解質(zhì)與酸堿平衡的維持,代謝中...[詳細(xì)]
造影劑腎病是碘造影劑應(yīng)用過程中的重要并發(fā)癥,也是醫(yī)源性腎功能衰竭的重要組成...[詳細(xì)]
意見反饋 關(guān)于我們 隱私保護(hù) 版權(quán)聲明 友情鏈接 聯(lián)系我們
Copyright 2002-2024 Iiyi.Com All Rights Reserved